Prognostic and clinicopathological significance of FOXD1 in various cancers: a meta and bioinformation analysis

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2023-09-07 DOI:10.2144/fsoa-2023-0085

Xiaohan Liu, Shengyun Min, Qin Zhang, Yan Liu, Zhenhong Zou, Nanye Wang, Bin Zhou

引用次数: 0

Abstract

Aim: To examine both predictive and clinicopathological importance underlying FOXD1 in malignant tumors, our study adopts meta-analysis. Methods: We searched from PubMed, Embase, WOS, Wanfang and CNKI. Stata SE15.1 was used to calculate the risk ratio (HR) as well as relative risk (RR) with 95% of overall confidence intervals (CIs) to assess FOXD1 and overall survival rate (OS), disease-free survival rate ( FOXD1) as well as clinicopathological parameters. Results: 3808 individuals throughout 17 trials showed high FOXD1 expression was linked to disadvantaged OS (p < 0.001) and disease-free survival (p < 0.001) and higher TNM stage (p < 0.001). Conclusion: Elevated FOXD1 had worse predictions and clinicopathological parameters in most cancers. The GEPIA database findings also support our results.

查看原文本刊更多论文

FOXD1在各种癌症中的预后和临床病理意义:meta和生物信息分析

目的:为了研究FOXD1在恶性肿瘤中的预测和临床病理意义，本研究采用荟萃分析。方法:检索PubMed、Embase、WOS、万方、中国知网。采用Stata SE15.1计算95%的总置信区间(ci)的风险比(HR)和相对风险(RR)，评估FOXD1和总生存率(OS)、无病生存率(FOXD1)以及临床病理参数。结果:17项试验中的3808例个体显示FOXD1高表达与不利OS相关(p <0.001)和无病生存率(p <0.001)和更高的TNM分期(p <0.001)。结论:FOXD1升高在大多数癌症中具有较差的预后和临床病理参数。GEPIA数据库的发现也支持我们的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries